Evidence Snapshot

Voltage-dependent L-type calcium channel subunit alpha-1C

CHEMBL1940 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1940

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent L-type calcium channel subunit alpha-1C as ChEMBL target CHEMBL1940, mapped to UniProt Q13936. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Voltage-dependent L-type calcium channel subunit alpha-1C

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1940

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q13936

Voltage-dependent L-type calcium channel subunit alpha-1C

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Voltage-dependent L-type calcium channel subunit alpha-1C matters

As of 2026-09-13

Voltage-dependent L-type calcium channel subunit alpha-1C is reviewed as Voltage-dependent L-type calcium channel subunit alpha-1C (UniProt Q13936); the current evidence base includes 33 approved drugs, 760 compounds, and 329 assays, with lead potency reaching pChEMBL 9.6.

Protein context

Voltage-dependent L-type calcium channel subunit alpha-1C

Voltage-dependent L-type calcium channel subunit alpha-1C Sequence length is 2221 aa.

Review this target as Voltage-dependent L-type calcium channel subunit alpha-1C, mapped to UniProt Q13936. Sequence length is 2221 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q13936 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 33 approved drugs, 760 compounds, and 329 assays for this target. The dominant activity type is IC50. CHEMBL475534 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL475534 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine

33 approved pChEMBL 9.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Voltage-dependent L-type calcium channel subunit alpha-1C matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13936, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

760

Total Compounds

329

Total Assays

Approved Drugs

IC50: 591.0, KI: 28.0, EC50: 3.0, KD: 24.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL475534	9.6	Ki	Clinical
No preferred name CHEMBL475534	9.6	Kd	Clinical
No preferred name CHEMBL193	9.4	Kd	Approved
No preferred name CHEMBL159854	9.0	Ki	—
No preferred name CHEMBL193	9.0	Ki	Approved

Approved Drugs

Structure	Compound	First Approval
	MIBEFRADIL CHEMBL45816	1997
	NISOLDIPINE CHEMBL1726	1995
	ISRADIPINE CHEMBL1648	1990
	NIMODIPINE CHEMBL1428	1988
	NICARDIPINE CHEMBL1484	1988
	NIFEDIPINE CHEMBL193	1981
	VERAPAMIL CHEMBL6966	1981
	CLOTRIMAZOLE CHEMBL104	1975
	TESTOSTERONE CHEMBL386630	1972

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1940